Manufacturing and clinical development strategies to expand access to CAR-T cell therapy for patients in India

“...maintaining consistent quality standards across multiple sites would be a challenge without central oversight, especially given India’s size and diverse patient pool.”

Abigail Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, talks to Amit Mookim, CEO, Immuneel Therapeutics, about ongoing efforts to expand access to affordable autologous CAR-T cell therapies across India and beyond.

Please enter your email to access content Read now